EUVIMEDEUVIMED entdecken
Crossref

ETS2 rs2836882 as predictor of biological therapy response in inflammatory bowel disease

M Brink, J Büttner, B Bochow-Fitzner, C Jochum

Zeitschrift für Gastroenterologie · 01.08.2026 · 64 (08) · e249-e250

DOI: 10.1055/s-0046-1826421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2026. Verfasst von M Brink und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims: Despite a growing number of treatment targets in Inflammatory Bowel Disease (IBD), a substantial proportion either does not respond to established therapies or loses therapeutic efficacy over time. Although genetic factors are known to contribute to IBD susceptibility, the influence of individual variants on treatment response remains largely unknown. Recent study has identified the transcription factor ETS2 as an important regulator of macrophage-driven inflammation and demonstrate that the genetic variants of a specific SNP rs2836882 modulate ETS2 expression. Based on this, we expected that genetic variation of rs283688 may influence response to biological therapy and investigated whether their impact with the efficacy of specific biological therapies. Methods: A retrospective cohort of 164 patients diagnosed with Crohn’s Disease (CD, n=110) and Ulcerative Colitis (UC, n=54) was genotyped for the rs2836882 variant. All patients had received at least one course of biological treatment with either TNF inhibitor or Vedolizumab (VDZ). Clinical data on therapy response and discontinuation was extracted from medical records and evaluated using survival and regression analyses ([ Abb. 1 ]). Abb. 1 Results: Patients carrying the GG genotype showed significant differences in treatment persistence comparing TNF inhibitors and VDZ (Log Rank, Breslow, Tarone-Ware p=

Zitieren

APA

Brink, M., Büttner, J., Bochow-Fitzner, B., & Jochum, C. (2026). ETS2 rs2836882 as predictor of biological therapy response in inflammatory bowel disease. Zeitschrift für Gastroenterologie, 64(08), e249-e250. https://doi.org/10.1055/s-0046-1826421

Vancouver

Brink M, Büttner J, Bochow-Fitzner B, Jochum C. ETS2 rs2836882 as predictor of biological therapy response in inflammatory bowel disease. Zeitschrift für Gastroenterologie. 2026;64(08):e249-e250. doi:10.1055/s-0046-1826421

BibTeX
@article{Brink2026,
  author = {Brink, M and Büttner, J and Bochow-Fitzner, B and Jochum, C},
  title = {ETS2 rs2836882 as predictor of biological therapy response in inflammatory bowel disease},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {08},
  pages = {e249--e250},
  doi = {10.1055/s-0046-1826421}
}
Kostenlos starten →